Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Celyad   /   celyad 2020

Aandeel Celyad BRU:CYAD.BL, BE0974260896

Laatste koers (eur) Verschil Volume
0,779   +0,009   (+1,17%) Dagrange 0,750 - 0,820 23.797   Gem. (3M) 85K

celyad 2020

Volgen
3.398 Posts
Pagina: «« 1 ... 140 141 142 143 144 ... 170 »» | Laatste | Omlaag ↓
  1. [verwijderd] 10 september 2020 16:51
    Ik schrik wel van dit artikel die Madduri en Atanackovic zijn toch vrij skeptisch over de allogene benadering (zoals van Celyad). Grotere risico's van GVHD. Eén zegt zelfs dat de Celyad methode eigenlijk niks nieuws is, maar slechts een andere manier om tot hetzelfde resultaat te komen als iets wat al bestaat.
    Ligt het aan mij of is dit echt een vrij negatief artikel? Dacht al enkele jaren dat we met Celyad bijna bij een doorbraak zijn.. Misschien verkeerd gedacht?
  4. Spreidstand 14 september 2020 07:32
    quote:

    Twin schreef op 14 september 2020 07:21:

    www.google.com/url?sa=t&source=we...
    Celyad Oncology Establishes At-the-Market Facility

    September 14, 2020 01:00 ET | Source: Celyad SA
    MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into an Open Market Sale AgreementSM with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, for a period of up to 36 months, through “an at the market offering” (“ATM”), with Jefferies acting as sales agent, up to $25,000,000 of new American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company, assuming sales of 2,522,704 ADSs in the offering at an offering price of $9.91 per ADS, which was the last reported sale price of the ADSs on the Nasdaq Global Market on September 8, 2020 . The actual number of ADSs issued will vary depending on the sales prices under this offering, however the number of ordinary shares shall not exceed 2,777,777 shares. The new ADSs will be sold at then current market prices. Sales of ADSs in the ATM will only be conducted in the United States through the Nasdaq Stock Market or any other existing U.S. trading market for the ADSs. No sales of ADSs will be conducted in Belgium or through Euronext.

    Celyad Oncology currently intends to use net proceeds from sales of ADSs in the ATM for general corporate purposes, including but not limited to the research and development of Company’s clinical and preclinical CAR T cell therapy candidates.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

    The securities are being offered pursuant to a shelf registration statement on Form F-3 (333-248464), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 4, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A prospectus supplement relating to the offering was filed by Celyad Oncology with the SEC on September 11, 2020 and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-547-6340 or by email at Prospectus_Department@Jefferies.com.

    About Celyad Oncology

    Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

    Forward-Looking Statement

    This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance, or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration, severity of the COVID-19 pandemic and government measures implemented in response thereto and whether any American Depositary Shares will be sold in the ATM and the use of proceeds therefrom. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

    Investor and Media Contacts:

    Alexandrine Hazard
    Communications & Investor Relations Associate
    Celyad Oncology
    investors@celyad.com

    Daniel Ferry
    Managing Director
    LifeSci Advisors, LLC
    daniel@lifesciadvisors.com

    Source: Celyad Oncology SA
  9. Garre 14 september 2020 09:20
    beter nu tegen deze koers als einde jaar op een hogere koers staan en dan een emissie doen die vaak een stuk lager ligt als de koers. We staan nu al op het niveau van de emissie, en we weten nu dat er weer genoeg geld in kas komt.
    Lijkt me tenminste, zie het ook liever hoger staan.
    Dart we nu even zakken komt denk ik dat er mensen toch even uitstappen vanuit onwetendheid wat de koers gaat doen, maar das alleen maar een idee, dat zie je wel vaker
  14. [verwijderd] 14 september 2020 16:51
    Zoals Twin zegt: "Hadden ze niet kunnen wachten tot einde jaar met goede resultaten?"
    Als er goed nieuws op komst is, wacht je normaal gesproken met een emissie; Want na goed nieuws vliegt de koers omhoog en kun je met hetzelfde aantal aandelen (dezelfde verwatering) veel meer geld ophalen aan een hogere koers. Dat ze het nu doen aan deze lage koers zonder nieuws, zou daarom geïnterpreteerd kunnen worden als dat er geen goed nieuws verwacht wordt binnenkort. Ik ben daarom skeptisch.
3.398 Posts
Pagina: «« 1 ... 140 141 142 143 144 ... 170 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee